Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

Merck is discontinuing a trial of once-monthly oral islatravir for PrEP. Participants will continue to be monitored, however, as the company still believes in the potential of long-acting HIV ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Merck (NYSE:MRK) recently announced the initiation of its Phase 3 EXPrESSIVE clinical trials for MK-8527, a new HIV prevention drug, reflecting its commitment to addressing global health challenges.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research ...

A path forward for Merck & Co.’s struggling HIV strategy has opened up, with the FDA releasing a nine-month clinical hold on trials of the Big Pharma’s drug islatravir as long as low doses are ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Merck has been at the forefront of innovation in HIV for decades, and we are excited to continue contributing to HIV research by exploring the development of longer-acting treatment and prevention ...

Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 Company to Proceed with Phase 2 Development ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an ...

Merck, known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and pharmacokinetics of the company’ s investigational ...